The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
J Diabetes Res. 2024 Mar 18;2024:5996218. doi: 10.1155/2024/5996218. eCollection 2024.
The Preferred Reporting Items for Systematic Reviews and Analysis checklist was used. A comprehensive literature search of the PubMed, Embase, and Cochrane Library databases was conducted through August 2022 to assess the impact of probiotics on blood glucose, lipid, and inflammatory markers in adults with prediabetes. Data were pooled using a random effects model and were expressed as standardized mean differences (SMDs) and 95% confidence interval (CI). Heterogeneity was evaluated and quantified as .
Seven publications with a total of 550 patients were included in the meta-analysis. Probiotics were found to significantly reduce the levels of glycosylated hemoglobin (HbA1c) (SMD -0.44; 95% CI -0.84, -0.05; = 0.03; = 76.13%, < 0.001) and homeostatic model assessment of insulin resistance (HOMA-IR) (SMD -0.27; 95% CI -0.45, -0.09; < 0.001; = 0.50%, = 0.36) and improve the levels of high-density lipoprotein cholesterol (HDL) (SMD -8.94; 95% CI -14.91, -2.97; = 0.003; = 80.24%, < 0.001), when compared to the placebo group. However, no significant difference was observed in fasting blood glucose, insulin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, interleukin-6, tumor necrosis factor-, and body mass index. Subgroup analyses showed that probiotics significantly reduced HbA1c in adults with prediabetes in Oceania, intervention duration of ≥3 months, and sample size <30.
Collectively, our meta-analysis revealed that probiotics had a significant impact on reducing the levels of HbA1c and HOMA-IR and improving the level of HDL in adults with prediabetes, which indicated a potential role in regulating blood glucose homeostasis. However, given the limited number of studies included in this analysis and the potential for bias, further large-scale, higher-quality randomized controlled trials are needed to confirm these findings. This trial is registered with CRD42022358379.
使用了系统评价和分析首选报告项目清单。通过 2022 年 8 月对 PubMed、Embase 和 Cochrane Library 数据库进行全面文献检索，评估益生菌对糖尿病前期成年人血糖、血脂和炎症标志物的影响。使用随机效应模型汇总数据，并表示为标准化均数差（SMD）和 95%置信区间（CI）。评估和量化异质性作为.
纳入了 7 项研究，共 550 名患者的研究被纳入荟萃分析。益生菌显著降低糖化血红蛋白（HbA1c）水平（SMD -0.44；95%CI -0.84，-0.05； = 0.03； = 76.13%， < 0.001）和稳态模型评估的胰岛素抵抗（HOMA-IR）（SMD -0.27；95%CI -0.45，-0.09； < 0.001； = 0.50%， = 0.36%），并提高高密度脂蛋白胆固醇（HDL）水平（SMD -8.94；95%CI -14.91，-2.97； = 0.003； = 80.24%， < 0.001），与安慰剂组相比。然而，空腹血糖、胰岛素、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、白细胞介素-6、肿瘤坏死因子-α和体重指数无显著差异。亚组分析显示，在大洋洲、干预时间≥3 个月和样本量<30 的糖尿病前期成年人中，益生菌显著降低了 HbA1c。
总的来说，我们的荟萃分析表明，益生菌对降低糖尿病前期成年人的 HbA1c 和 HOMA-IR 水平以及提高 HDL 水平有显著影响，这表明其在调节血糖稳态方面可能具有一定作用。然而，鉴于本分析纳入的研究数量有限且存在偏倚的可能性，需要进一步开展大规模、高质量的随机对照试验来证实这些发现。该试验已在 CRD42022358379 注册。
